TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06350448
Drug: Washed Microbiota Transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washed microbiota suspension (5U) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5U, three times.
Study: NCT04793399
Drug: Bosutinib 400 MG Monotherapy
Normalized name: bosutinib 400 MG
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
Study: NCT04793399
Drug: Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection
Normalized name: atezolizumab
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
Study: NCT04828135
Drug: Hyperpolarized 129Xenon gas
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
Study: NCT06007417
Drug: Genotropin
Normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin
Study: NCT05986266
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
Study: NCT01288625
Drug: Amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg sc, qod, 3 times per week
Study: NCT05842525
Drug: intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off Irinotecan 150 mg/m2 LV 400 mg/m2 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 on day 1, q2w （intensive treatment up to 8 cycels）
Study: NCT06059677
Drug: Active smoked cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of active cannabis smoking and driving impairment
Study: NCT06059677
Drug: Placebo smoked cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of placebo cannabis smoking and driving impairment
Study: NCT05459441
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
Study: NCT04718350
Drug: levosimendan at a dose of 6 mcg/kg
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
Study: NCT04718350
Drug: milrinone at a dose of 50 mcg/kg
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
Study: NCT04375956
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental
Study: NCT05548985
Drug: Midodrine Oral Tablet
Normalized name: midodrine Oral Tablet
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral midodrine tablet (5 mg) 90 min before performing spinal block
Study: NCT05548985
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
Study: NCT05751148
Drug: Hyperbaric prilocaïne
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
Study: NCT05325762
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
Study: NCT05325762
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
Study: NCT05325762
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
Study: NCT05267535
Drug: Piromelatine 20 mg
Normalized name: Piromelatine
DrugBank: Piromelatine (DB12288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT02412566
Drug: SMOFlipid
Normalized name: Smoflipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
Study: NCT04777162
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For included participants, tislelizumab would be administrated 200mg q3w iv.
Study: NCT04777162
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
Study: NCT03646058
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine, 0.4mg pills, sublingual
Study: NCT04289558
Drug: Sodium Nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
Study: NCT06634394
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet given on days 1 through 22, of a 28 day cycle.
Study: NCT06634394
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion given on days 1-8 of a 28 day cycle
Study: NCT06390046
Drug: TIVA versus Inhalation
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparing TIVA with genera anesthesia with inhalation agent
Study: NCT04799002
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan intraocular injection for chemotherapy in retinoblastoma
Study: NCT04799002
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan intraocular injection for chemotherapy in retinoblastoma
Study: NCT05346328
Drug: Injection of A166
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
DrugBank: A166 (DB17413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 mg/kg for each 21 (±3) -day cycle
Study: NCT04930315
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery
Study: NCT04930315
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, iv, d1, q2w, both in two groups
Study: NCT05071612
Drug: AD109
Normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration at bedtime
Study: NCT05071612
Drug: AD504
Normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration at bedtime
Study: NCT05071612
Drug: Atomoxetine Hydrochloride
Normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration at bedtime
Study: NCT05155124
Drug: Cetuximab + trifluridin tipiracil
Normalized name: tipiracil / trifluridine
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
Study: NCT06131905
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
Study: NCT06131905
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
Study: NCT05922995
Drug: Tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg capsules taken on a nightly basis
Study: NCT06133881
Drug: prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
Study: NCT06133881
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
Study: NCT04739111
Drug: Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
Study: NCT04963283
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
Study: NCT04963283
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
Study: NCT04074512
Drug: Copper Histidinate
Normalized name: Histidine
DrugBank: Copper (DB09130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Restoring Copper Histidinate levels normally found in the blood to assist in the maintenance of copper homeostasis.
Study: NCT00334503
Drug: Miglitol
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05042401
Drug: SHR-1703
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1703 low dose
Study: NCT05042401
Drug: SHR-1703
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1703 high dose
Study: NCT05411107
Drug: Iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05173012
Drug: SAGE-324
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-324 oral tablets.
Study: NCT05173012
Drug: SAGE-324 Matched Placebo
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-324 matched placebo oral tablets.
Study: NCT04873440
Drug: Manganese Chloride
Normalized name: Manganese Chloride
DrugBank: Manganese citrate (DB14495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by inhalation at 0.4mg/kg/d twice a week
Study: NCT03110484
Drug: Pemetrexed 500 MG
Normalized name: pemetrexed 500 MG
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2
Study: NCT03110484
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 100mg once daily
Study: NCT05394610
Drug: Sana Device (Control)
Normalized name: Sana leaf
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A control device that mimics the physcial appearance of the Sana device.
Study: NCT05975346
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: description
Study: NCT06411093
Drug: Conventional treatment including silver nitrate cauterization
Normalized name: Silver Nitrate
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional treatment including silver nitrate cauterization, with or without topical antiseptics, topical steroids, topical beta-blockers, short-term systemic antibiotics, systemic steroids for 3 months
Study: NCT06281977
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
Study: NCT06348303
Drug: Metaxalone m640 mg oral tablet
Normalized name: Metaxalone
DrugBank: Metaxalone (DB00660)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaxalone partially micronized 640 mg tablet
Study: NCT06348303
Drug: Metaxalone 800 mg oral tablet
Normalized name: METAXALONE 800 mg ORAL TABLET
DrugBank: Metaxalone (DB00660)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaxalone non-micronized 800 mg oral tablet
Study: NCT06186583
Drug: Pimicotinib（ABSK021）
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
Study: NCT00002343
Drug: Ethambutol hydrochloride
Normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002343
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06482775
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dosing and administration will be implemented according to an algorithm based on pain scoring results
Study: NCT04966234
Drug: Posaconazole 100 MG [Noxafil]
Normalized name: posaconazole 100 MG [Noxafil]
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile
Study: NCT04966234
Drug: Posaconazole 40 MG/ML
Normalized name: posaconazole 40 MG/ML
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile
Study: NCT05180214
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: analgesic
Study: NCT04729348
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral, daily, dosage per protocol
Study: NCT04729348
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral, daily, dosage per protocol
Study: NCT06094309
Drug: Botulinum toxin type A injection
Normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
Study: NCT05210504
Drug: L-Lysine
Normalized name: L-Lysine
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5g L-lysine in 50ml water, administered orally
Study: NCT05951647
Drug: Chamomile extract mouthwash
Normalized name: chamomile extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% chamomile extract mouthwash in a dose of 15 ml twice daily.
Study: NCT05951647
Drug: Pomegranate peel extract mouth wash
Normalized name: pomegranate extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.
Study: NCT05951647
Drug: Combination of 5% chamomile extract and pomegranate peel extract mouthwash
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.
Study: NCT05951647
Drug: Scaling and Chlorohexidine mouthwash
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.
Study: NCT06334874
Drug: Astaxanthin Oral Capsule
Normalized name: astaxanthin Oral Capsule
DrugBank: Astaxanthin (DB06543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of astaxanthin oral capsule
Study: NCT04854811
Drug: Roflumilast Oral Tablet
Normalized name: roflumilast Oral Tablet
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily for 12 weeks
Study: NCT06300177
Drug: D-1553 Tablet
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-1553 is a KRAS inhibitor.
Study: NCT06300177
Drug: Docetaxel injection
Normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.
Study: NCT04922983
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).
Study: NCT05268614
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive 40 mg/m2 of cisplatin intravenously over 60 minutes weekly during radiation therapy.~If cisplatin is not recommended by the treating medical oncologist or is not tolerated, it is permissible to switch to an alternative chemotherapy regimen per institutional practice, but chemotherapy should not be discontinued unless mandated by the patient's condition.
Study: NCT05698147
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death.